Trial reportBlood cancer journal2017
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IILetter
In one paragraph
Trial report in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 52 citations in OpenAlex.
- Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.Acta haematologica · 2019Trial
- Calcium and Other Electrolyte Management in Patients Undergoing Leukocytapheresis Collections: Review and Recommendations From the American Society for Apheresis Clinical Applications Committee.Journal of clinical apheresis · 2026Review
- The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia.Biomedicines · 2026Review
- Review
- From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.Bone research · 2026Review
- CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization.Scientific reports · 2025Article
- Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.MedComm · 2025Review
- Oncogenic and microenvironmental signals drive cell type specific apoptosis resistance in juvenile myelomonocytic leukemia.Cell death & disease · 2025Article
- Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML.HemaSphere · 2023Article
- The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8Biomedicines · 2022Review
- Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia.Scientific reports · 2021Article
- Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives.Cancers · 2021Review
- Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.Experimental hematology & oncology · 2021Review
- Role of CXCR4 in the progression and therapy of acute leukaemia.Cell proliferation · 2021Review
- Leukaemia: a model metastatic disease.Nature reviews. Cancer · 2021Review
- Insights Into Bone Marrow Niche Stability: An Adhesion and Metabolism Route.Frontiers in cell and developmental biology · 2021Review
- Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.Stem cells translational medicine · 2020Review
- Review
- Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance.Haematologica · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
G L UyDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-7809-0996
M P RettigDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
R M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
M Y KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K McFarlandDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
W ShannonDivision of General Medical Sciences, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
T R FletcherDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
T ReineckDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
W EadesDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
K Stockerl-GoldsteinDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-7234-1715
C N AbboudDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
M A JacobyDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
P WesterveltDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
J F DiPersioDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Washington University in St. Louis · USThe University of Texas MD Anderson Cancer Center · USDana-Farber Cancer Institute · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MTARGETING AML-STROMAL INTERACTIONSR01CA152329 · NCI · WASHINGTON UNIVERSITY · PI DIPERSIO, JOHN F. · 2011 to 2015
$2.5MBM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3MTargeting Leukemia Stromal Interactions in AMLK23CA140707 · NCI · WASHINGTON UNIVERSITY · PI UY, GEOFFREY L · 2009 to 2013
$793kTARGETING THE CXCR4-SDF1 AXIS AS THERAPY FOR RELAPSED/REFRACTORY AMLR21CA132269 · NCI · WASHINGTON UNIVERSITY · PI DIPERSIO, JOHN F. · 2009 to 2010
$669kOPTIMIZING ALLOGENEIC TRANSPLANTATION USING CXCR4 BLOCKADER21CA141523 · NCI · WASHINGTON UNIVERSITY · PI DIPERSIO, JOHN F. · 2009 to 2010
$669kNCI NIH HHS K23 CA140707NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA152329NCI NIH HHS R21 CA132269NCI NIH HHS R21 CA141523NCI NIH HHS R50 CA211466
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hematopoietic Stem Cell MobilizationStem Cell TransplantationAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAutograftsBenzylaminesCyclamsCytarabineEtoposideFemaleGranulocyte Colony-Stimulating FactorHeterocyclic CompoundsHumansLeukemia, Myeloid, AcuteBenzylaminesCyclamsCytarabineEtoposideGranulocyte Colony-Stimulating FactorHeterocyclic CompoundsMitoxantroneplerixafor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.